A5014503184- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Vibrio bacteria research studies
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Pancreatic function and diabetes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Bacteriophages and microbial interactions
- Hepatitis Viruses Studies and Epidemiology
- HIV Research and Treatment
- Animal Virus Infections Studies
- Pancreatitis Pathology and Treatment
- Immunodeficiency and Autoimmune Disorders
University Medical Center
2020-2025
Leipzig University
2017-2025
University Hospital Leipzig
2017-2020
Center for Rheumatology
2017
Ancient DNA traces the history of hepatitis B Hepatitis virus (HBV) infections represent a worldwide human health concern. To study this pathogen, Kocher et al . identified 137 remains with detectable levels dating between 400 and 10,000 years ago. Sequencing analyses these ancient viruses suggested common ancestor 12,000 20,000 There is no evidence indicating that HBV was present in earliest humans as they spread out Africa; however, likely populations before farming. Furthermore, Americas...
Objective Among individuals with chronic hepatitis B, those B e-antigen (HBeAg)-negative (CHB) can be difficult to distinguish from HBeAg-negative HBV infection, also referred as inactive carriers (ICs), but both require different medical management. The level of surface antigen (HBsAg) has been proposed a marker discriminate between infection and stages. HBsAg consists large, middle small HBs. aim this study was determine whether the composition improved identification ICs among...
Hepatitis B virus (HBV) RNA in serum is a novel biomarker for intrahepatic HBV replication and treatment response. For its proper use, it essential to identify factors influencing level. Using rapid amplification of complimentary DNA (cDNA) ends (RACE) PCR technique (lower limit detection [LLD], 800 copies/mL [c/mL]), levels were measured samples 488 untreated individuals with chronic infection who eligible according currently used recommendations. We explored the association patient‐...
Hepatitis B virus RNA (HBV-RNA) is a novel serum biomarker that correlates with transcription of intrahepatic covalently closed circular (cccDNA), which an important target for pegylated interferon (PEG-IFN) and therapies functional cure. We studied HBV-RNA kinetics following PEG-IFN treatment its potential role as predictor to response in HBeAg-negative chronic hepatitis (CHB) patients.HBV-RNA levels were measured 133 CHB patients treated international randomized controlled trial (PARC...
Abstract Hepatitis B virus (HBV) RNA in serum is a novel biomarker that reflects cccDNA activity. We investigated whether HBV can predict serological response to peginterferon (PEG‐IFN) treatment. Serum levels were retrospectively measured at weeks 0, 12, 24 and 52 of therapy after treatment discontinuation (week 78) 266 HBeAg‐positive chronic patients who had participated global randomized controlled trial (HBV99‐01 study). Patients received PEG‐IFN monotherapy (n = 136) or lamivudine 130)....
Background The African specific HBV genotype E (HBVgtE) is associated to a relative high viral replication and greater risk of hepatocellular carcinoma. However, studies concerning this are still under-represented. This project aims at generating competent DNA plasmid better understand biomarker production pathogenesis by in vitro.
HBsAg proteins are useful to identify HBV inactive carriers (ICs), but data on chronic hepatitis D (CHD) scarce. This study aimed describe composition in CHD, its changes during the evolution, and potential association with clinical outcomes. In addition, we assess of across different genotypes validate previous results an independent cohort.Quantitative HBsAg, medium (MHBs), large (LHBs) were measured two cohorts. The first cohort consisted patients CHD. A cross-sectional samples from...
The presence of precore (PC) and BCP variants is associated with HBeAg seroconversion (SC) during treatment PEG-IFN, but the mechanism SC still unknown. We investigated occurrence BCP/PC PEG-IFN their association replication response. Therefore, patients positive chronic hepatitis B receiving for 48 weeks (39 28 without until week 72) were retrospectively analysed. Viral markers (HBeAg, HBcrAg, HBsAg, HBV DNA RNA) quantified (A1762T/G1764A) PC stop (G1896A) analysed by direct sequencing on...
Das Vorhandensein von „pre-core“ (PC) und „basal core promotor“ (BCP)-Varianten im Genom des Hepatitis-B-Virus (HBV) ist mit dem Ansprechen auf eine Behandlung pegyliertem Interferon (PEG-IFN) alfa assoziiert. Wir haben untersucht, ob diese Varianten unter einer PEG-IFN weiter selektioniert werden sie ein Marker für sein können.
Since functional cure of HBV occurs rarely in HBeAg negative patients during treatment with pegylated Interferon-alpha (PEG-IFN), a transformation into disease stage lower replication might be considered an alternative goal. HBsAg consists the components large (L), middle (M) and small (S)HBs, composition shows strong association to stages. We have investigated whether kinetics MHBs or LHBs serum is associated response PEG-IFN treatment.
Der HBsAg-Verlust oder die Serokonversion (SC) während der Behandlung mit Nukleos(t)id-analoga (NA) pegyliertem Interferon-alfa (PEG-IFN) wird als funktionelle Heilung angesehen. HBsAg besteht aus dem großen (L), mittleren (M) und kleinen (S)HBs. Bei Patienten im inaktiven Trägerstatus zeigt sich ein stark verminderter Anteil von LHBs MHBs Vergleich zu anderen Krankheitsstadien. Wir haben untersucht, ob bei Patienten, unter NA- bzw. IFN-basierter Therapie eine erreichen, frühzeitige Änderung...
Background and aims The surface antigen of hepatitis B virus (HBV), HBsAg, consists the components large (L), middle (M) small (S)HBs. composition HBsAg differs across disease stages, is an early marker for treatment induced loss possibly a HBV integration. However, role in life cycle largely unknown. We aimed at establishing vitro model infections based on primary human hepatocytes (PHHs) patient-derived to investigate proteins during natural course infections.
Question The hepatitis B surface antigen (HBsAg) consists of the components small (SHBs), middle (MHBs) and large (LHBs) HBsAg. Recently, we could show that HBsAg loss during nucleos(t)ide analogue (NA) treatment are preceded by decreases LHBs MHBs ratios. In this study, investigated association between composition changes in their protein amino acids sequences within HBV s gene process NA treatment.